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Summary 
Eighteen patients with advanced epidermoid carcinoma of  the head and neck were entered into a phase II 
trial of N-Methylformamide (NMF), 800 mg/M 2 IV daily for 5 days every 4 weeks. Seventeen patients had 
received prior radiation therapy and 11 were previously treated with chemotherapy. No complete or partial 
responses were observed. The major toxicity was gastrointestinal. Fifty percent of  patients experienced 
nausea and vomiting or reversible hepatotoxicity with greater than a 3-fold elevation of  liver enzymes. Mild 
reversible myelosuppression occurred in 2 patients. NMF in this dose and schedule was not a useful agent 
to treat recurrent epidermoid carcinoma of  the head and neck. 
Introduction 
N-Methylformamide (NMF) is a metabolite of 
dimethylformamide (DMF) a widely used industrial 
polar solvent. NMF was found to be cytotoxic in 
rodent tumor models [1, 2] and underwent clinical 
testing at Memorial Sloan Kettering Institute in 
1956. Five patients were treated with oral NMF, but 
treatment was discontinued due to hepatotoxicity 
[3]. Further study of  NMF was abandoned until 
Dexter et al. reported that N-dimethylformamide 
(DMF)-treated human colon carcinoma cell lines 
lost their ability to grow in soft agar and were less 
tumorigenic in athymic mice [4]. This differen- 
tiating ability rekindled interest in NMF and 
prompted testing against the National Cancer Insti- 
tute human tumor xenograft panel. Antitumor ac- 
tivity was observed against the MX 1 mammary 
tumor,  CX 1 colon tumor,  and LX 1 lung xeno- 
grafts. The drug was also effective against murine 
sarcoma 180, M5076 ovarian sarcoma, TLXS lym- 
phoma, AKR leukemia, and Ehrich ascites carcino- 
ma and only moderately active against L 1210 and 
P388 leukemias [5, 6]. 
Four Phase I clinical studies completed to date 
recommended doses of 800 mg/MZ/day X5 orally 
every 2 - 3  weeks [7], 2000 mg/MZ/week X3 IV [8] 
and 1,125 mg/MZ/week X6 IV [9], and 1000 
mg/MZ/day X5 IV every 3 - 4  weeks [10]. The dose 
limiting toxic effects included nausea, vomiting, 
anorexia, malaise, and liver function abnormali- 
ties. This study evaluated the antitumor activity of 
NMF in head and neck cancer using the phase I 5 
day intravenous bolus schedule studied by Spremul- 
li and Coworkers [10]. 
Methods and materials 
Eighteen patients with histologically confirmed 
epidermoid carcinoma of  the head and neck were 
entered in the study. All patients had measurable 
disease, a Karnofsky performance score of  at least 
50~ an expected survival of  at least 8 weeks, 
wbc count > 3500 cells/mm 3, platelet count > 
100,000/~d, serum creatinine < 2.5 mg%, serum 
bilirubin < 2.0 mg and SGOT and SGPT not ele- 
vated more than twice normal. A chest roentgeno- 
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gram, electrocardiogram, alkaline phosphatase, 
SGOT, SGPT, LDH, bilirubin, total protein, albu- 
min, uric acid, PT, PTT and urinalysis were ob- 
tained prior to each cycle. Patients with an unstable 
cardiac status were excluded because of  the risk 
of  myocardial damage reported in pre-clinical 
screening. The initial dose of  NMF was 800 mg/M 2 
diluted to a volume of  250 ml D5W in glass bottles 
administered by peripheral IV infusion over 15 
minutes daily for 5 days. Treatment was repeated 
every 4 weeks. Dose modifications were based on 
gastrointestinal (GI) toxicity of  the preceding cycle. 
In the absence of  toxicity, 2 dose escalations of  100 
mg/M 2 each cycle for a maximum of  1000 mg/M 2 
x 5 days were allowed. If  liver function tests 
(LFTs) were abnormal but elevated tess than 3 times 
normal, the same dose of  NMF was given. If  the 
LFTs became greater than 3 times normal during 
the 5 daily treatments, NMF was held until LFTs 
returned to normal. For Southwest Oncology 
Group grade 2 GI toxicity (abdominal pain; consti- 
pation for 2 - 4  days; diarrhea producing greater 
than 4 liquid stools; and more than 5 vomiting 
episodes in 24 hours) treatment was withheld until 
toxicity resolved and reinstituted at a 25~ dose 
reduction. Liver function tests were measured daily 
during treatment, then every two weeks, CBC and 
platelet counts were performed every two weeks 
and measurable disease parameters were assessed 
every 4 weeks. An adequate trial required one cycle 
and 4 weeks survival. Standard response criteria 
defined in previous trials were used [11]. 
Results 
Patient characteristics are shown in Table 1. Of  
the 18 patients entered on study, 17 had recurrent 
disease and one was newly diagnosed with ad- 
vanced, incurable disease. Seven patients had not 
received prior chemotherapy. Patients at our insti- 
tution were initially started at an NMF dose of  1000 
mg/M2/day  x 5. Three patients were entered at 
this dose. In concurrent evaluation of NMF in lung 
cancer patients at our institution, one patient 
receiving 1000 mg/M2/day  x 5 days developed 
severe hepatotoxicity with a total bilirubin of  4.9 
Table 1. Patient characteristics 
No. o f  patients 
Total  18 




Median performance status (range) 70 (60-90) 
Prior t reatment  
Surgery + RT 6 
RT + Cherno 5 
Surgery + RT + Chemo 6 
No Prior Treatment  1 
Pr imary site 
Oropharynx 4 
Skin 1 
Oral Cavity 4 





Sites o f  measureable disease 








mg/dl  (normal range 0 .1 -0 .9  mg/dl),  alkaline 
phosphatase 647 (30-96 IU), SGOT 117 (2-35  IU), 
SGPT 440 (2-35  IU) and right upper quadrant ab- 
dominal pain, nausea, vomiting and anorexia [12]. 
All subsequent patients entering NMF protocols 
were started at 800 mg/M2/day x 5 days. 
Eighteen patients were evaluable for response 
and toxicity. No complete or partial responses were 
observed; 12 patients rapidly progressed after only 
1 cycle. A total of 24 cycles were administered. 
Toxicities consisted of  grade 1 nausea and vomiting 
in 3 patients, grade 2 in 2 patients, grade 3 in 4 pa- 
tients. Elevation of  SGOT 3 x baseline was seen in 
4/24 cycles, SGPT 3 x baseline in 7/24, alkaline 
phosphatase 3 • baseline in 3/24. LDH and total 
bilirubin were not elevated greater than 3 • base- 
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Table 2. Toxicity 
Dose No. of  No. of  
pts cycles 
No. of  patients 
Nausea and vomiting 
Grade 1 Grade 2 Grade 3 
600 m g / M  2 1 1 0 0 
800 m g / M  2 15 17 1 2 
900 m g / M  z 1 1 1 0 
1000 m g / M  2 4 5 1 0 
Hepatotoxicity 
LFTs 3 x baseline 
600 m g / M  2 1 1 0 
800 m g / M  2 15 17 10" 
900 m g / M  2 1 1 0 
1000 m g / M  2 4 5 1 
*One patient receiving 800 mg /M2/day  x 5 days had severe hepatotoxicity with LFTs 100 x baseline. 
line in any of  24 cycles. One patient had SGOT and 
SGPT elevation greater than 100 x baseline. This 
patient was removed from study secondary to 
hepatotoxicity. The LFTs did return to baseline. 
Two patients had persistent elevation of SGOT, 
SGPT and alkaline phosphatase which delayed 
retreatment. Nine of 18 patients developed nausea 
and vomiting. Nausea and vomiting was associated 
with liver enzyme elevation in 6 of  9 patients. Mye- 
losuppression occurred in two patients, nadir WBC 
count 3,000 and 3,200 and nadir platelet count 
62,000 and 35,000. Two patients had dosage escala- 
tions, one from 800 mg/ME/day to 1000 mg/M 2, 
and the second from 800 mg/ME/day to 900 
mg/M2/day.  One patient had a dosage decrease 
from 800 mg/ME/day to 600 mg/M2/day due to 
hepatotoxicity. 
tients had no prior chemotherapy. Rapid progres- 
sion of disease was seen in 12 patients after one dose 
of  NMF. The major toxicity which was treatment- 
limiting was hepatotoxicity. We conclude that 
NMF in the present dose and schedule is not a use- 
ful agent for the treatment of  epidermoid carcino- 
ma of the head and neck. 
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Discussion 
In this phase II trial of  NMF for advanced epider- 
moid carcinoma of  the head and neck no clinical 
responses were observed. This excludes a 20% 
response rate with 95~ confidence. All patients 
except one had prior treatment that included radia- 
tion therapy although forty percent (7/18) of pa- 
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